Logo image of KRMD

KORU MEDICAL SYSTEMS INC (KRMD) Stock Fundamental Analysis

NASDAQ:KRMD - Nasdaq - US7599101026 - Common Stock - Currency: USD

3.02  -0.06 (-1.95%)

Fundamental Rating

3

KRMD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. While KRMD seems to be doing ok healthwise, there are quite some concerns on its profitability. KRMD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

KRMD had negative earnings in the past year.
In the past year KRMD has reported a negative cash flow from operations.
KRMD had negative earnings in each of the past 5 years.
In the past 5 years KRMD always reported negative operating cash flow.
KRMD Yearly Net Income VS EBIT VS OCF VS FCFKRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

KRMD has a Return On Assets (-19.46%) which is in line with its industry peers.
With a Return On Equity value of -32.41%, KRMD perfoms like the industry average, outperforming 54.26% of the companies in the same industry.
Industry RankSector Rank
ROA -19.46%
ROE -32.41%
ROIC N/A
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
KRMD Yearly ROA, ROE, ROICKRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

The Gross Margin of KRMD (63.49%) is better than 63.83% of its industry peers.
KRMD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for KRMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
KRMD Yearly Profit, Operating, Gross MarginsKRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60

5

2. Health

2.1 Basic Checks

KRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KRMD has more shares outstanding
KRMD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for KRMD has been reduced compared to a year ago.
KRMD Yearly Shares OutstandingKRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
KRMD Yearly Total Debt VS Total AssetsKRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

KRMD has an Altman-Z score of 7.21. This indicates that KRMD is financially healthy and has little risk of bankruptcy at the moment.
KRMD has a Altman-Z score of 7.21. This is amongst the best in the industry. KRMD outperforms 85.64% of its industry peers.
KRMD has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of KRMD (0.02) is better than 65.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 7.21
ROIC/WACCN/A
WACC9.15%
KRMD Yearly LT Debt VS Equity VS FCFKRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

KRMD has a Current Ratio of 2.44. This indicates that KRMD is financially healthy and has no problem in meeting its short term obligations.
KRMD has a Current ratio (2.44) which is in line with its industry peers.
A Quick Ratio of 2.02 indicates that KRMD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.02, KRMD is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.02
KRMD Yearly Current Assets VS Current LiabilitesKRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.08% over the past year.
KRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.63%.
KRMD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.76% yearly.
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)19.63%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%17.53%

3.2 Future

The Earnings Per Share is expected to grow by 34.04% on average over the next years. This is a very strong growth
Based on estimates for the next years, KRMD will show a quite strong growth in Revenue. The Revenue will grow by 16.49% on average per year.
EPS Next Y0.04%
EPS Next 2Y26.66%
EPS Next 3Y34.04%
EPS Next 5YN/A
Revenue Next Year15.67%
Revenue Next 2Y15.14%
Revenue Next 3Y16.49%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
KRMD Yearly Revenue VS EstimatesKRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
KRMD Yearly EPS VS EstimatesKRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.05 -0.1 -0.15 -0.2

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KRMD. In the last year negative earnings were reported.
Also next year KRMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRMD Price Earnings VS Forward Price EarningsKRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRMD Per share dataKRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

KRMD's earnings are expected to grow with 34.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.66%
EPS Next 3Y34.04%

0

5. Dividend

5.1 Amount

KRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

KORU MEDICAL SYSTEMS INC

NASDAQ:KRMD (6/9/2025, 8:00:02 PM)

3.02

-0.06 (-1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)N/A N/A
Inst Owners51.03%
Inst Owner ChangeN/A
Ins Owners6.35%
Ins Owner Change8.46%
Market Cap139.34M
Analysts80
Price Target5.61 (85.76%)
Short Float %0.8%
Short Ratio2.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.23%
Min EPS beat(2)3.88%
Max EPS beat(2)24.59%
EPS beat(4)4
Avg EPS beat(4)26.1%
Min EPS beat(4)3.88%
Max EPS beat(4)53.31%
EPS beat(8)8
Avg EPS beat(8)29.24%
EPS beat(12)12
Avg EPS beat(12)26.13%
EPS beat(16)14
Avg EPS beat(16)19.99%
Revenue beat(2)1
Avg Revenue beat(2)1.97%
Min Revenue beat(2)-2.56%
Max Revenue beat(2)6.5%
Revenue beat(4)3
Avg Revenue beat(4)4.38%
Min Revenue beat(4)-2.56%
Max Revenue beat(4)9.18%
Revenue beat(8)5
Avg Revenue beat(8)0.92%
Revenue beat(12)7
Avg Revenue beat(12)1.39%
Revenue beat(16)11
Avg Revenue beat(16)2.24%
PT rev (1m)-3.51%
PT rev (3m)-3.51%
EPS NQ rev (1m)15.38%
EPS NQ rev (3m)8.33%
EPS NY rev (1m)0.61%
EPS NY rev (3m)-12.64%
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)1.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.97
P/FCF N/A
P/OCF N/A
P/B 8.53
P/tB 8.92
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.76
BVpS0.35
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.46%
ROE -32.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.49%
FCFM N/A
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
F-Score5
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 189.27%
Cap/Sales 4.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.44
Quick Ratio 2.02
Altman-Z 7.21
F-Score5
WACC9.15%
ROIC/WACCN/A
Cap/Depr(3y)239.72%
Cap/Depr(5y)210.83%
Cap/Sales(3y)5.63%
Cap/Sales(5y)4.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y0.04%
EPS Next 2Y26.66%
EPS Next 3Y34.04%
EPS Next 5YN/A
Revenue 1Y (TTM)19.63%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%17.53%
Revenue Next Year15.67%
Revenue Next 2Y15.14%
Revenue Next 3Y16.49%
Revenue Next 5YN/A
EBIT growth 1Y37.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.88%
EBIT Next 3Y41.31%
EBIT Next 5YN/A
FCF growth 1Y82.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.47%
OCF growth 3YN/A
OCF growth 5YN/A